The Factor V Gene A4070G Mutation and the Risk of Venous Thrombosis

Summary

The A4070G polymorphism in exon 13 of the factor V (FV) gene, which replaces His by Arg at position 1299 of the B domain, was recently shown to influence circulating FV levels and to contribute to the activated protein C (APC) resistance phenotype. We examined the impact of this polymorphism in a population of unselected patients with venous thromboembolic disease (VTE). The prevalence of the G4070 (R2) allele was determined in 205 patients and 394 healthy subjects of similar age and sex distribution. Thirty-seven patients (18%) were heterozygous for the R2 allele and 1 (0.5%) was homozygous. Forty-four controls (11.2%) were heterozygous for the R2 allele and 1 (0.2%) was homozygous. Thus, the allelic frequency was significantly higher in the patients with VTE than in the healthy controls, with respective values of 9.5% and 5.8%. The odds ratio was 1.8 (95% CI: 1.1-2.8, p = 0.02), pointing to an increased risk of VTE in carriers of the R2 allele. After excluding subjects with putative or confirmed gene defects (mainly the FV R506Q mutation), the R2 allele was still a risk factor for VTE in the remaining patients, with an odds ratio of 2.0 (95% CI: 1.2-3.5, p = 0.01), demonstrating that this polymorphism is itself a risk factor. This study also confirms that the R2 allele influences APC resistance (APCR) in the absence of the FV R506Q mutation.

• References

• 1 Hoyer LW, Wyshock EG, Colman RW. Coagulation cofactors: factors V and VIII. Colman RW, Hirsh J, Marder VJ, Salzman JB EW. eds Philadelphia: Lippincott Company; 1994: 109-33.
• 2 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in the FV R506Q. J Biol Chem 1995; 270: 4053-7.
• 3 Shen L, Dahlbäck B. Factor V and protein S as synergic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
• 4 Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
• 5 Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor V R506Q mutation. Thromb Haemost 1996; 76: 208-14.
• 6 Thorelli E, Kaufman RJ, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140-5.
• 7 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
• 8 Dahlbäck B. Resistance to activated protein C caused by the factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-8.
• 9 Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
• 10 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 11 Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506Gln mutation in the factor V gene. Biochem J 1996; 313: 467-72.
• 12 Roelse JC, Koopman MMW, Büller HR, ten Cate JW, Montaruli B, van Mourik JA, Voorberg J. Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Brit J Haematol 1996; 92: 740-3.
• 13 Bokarewa I M, Falk G, Bremme K, Blomback M, Wiman B. Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance. Eur J Clin Invest 1997; 27: 340-5.
• 14 Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
• 15 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 to Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
• 16 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-85.
• 17 Lunghi B, Iacovello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
• 18 Bernardi F, Faioni EM, Castoldi E, Lunghi B, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
• 19 Working group on haemostasis of the Société Française de Biologie Clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost 1993; 70: 781-6.
• 20 Van Dreden P, Thuillier N, Amiral J, Bouyé M, Martinoli JL. Development and evaluation of a new activated protein C resistance assay: Staclot APC-R. Thromb Haemost 1997; 78: 20 (abstr).
• 21 Vasse M, Van Dreden P, Thuillier N, Bouyé M, Vannier JP. A new chronometric assay based on the Va-dependent procoagulant activity of a snake venom for the detection of factor V Leiden. Thromb Haemost 1997; 78: 21 (abstr).
• 22 Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coag Fibrinol 1995; 6: 245-9.
• 23 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
• 24 Simioni P, Scarano L, Gavasso S, Sardella C, Girolami B, Scudeller A, Girolami A. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-41.
• 25 Zoller B, Holm J, Svensson P, Dahlbäck B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg 506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
• 26 Martinelli I, Bottasso B, Duca F, Faioni E, Mannucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-5.
• 27 Bertina RM. Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thromb Haemost 1997; 78: 478-82.
• 28 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation of the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 29 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3' untranslated region of the prothrombin gene. Brit J Haematol 1997; 98: 907-9.
• 30 Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Brit J Haematol 1997; 98: 353-5.
• 31 Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78: 990-2.
• 32 Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D. Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998; 80: 49-51.
• 33 Oger E., Leroyer C, Mercier B, van Dreden P, Bressollette L, de Saint-Martin L, Le Moigne E, Blouch MT, Thuillier N, Amiral J, Ferec C, Abgrall JF, Mottier D. Assessment of activated protein C resistance using a new and rapid venom-base test: STA Staclot APC-R. Blood Coag Fibrinol 1998; 9: 355-9.
• 34 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinol 1996; 7: 761-5.
• 35 Henkens CMA, Bom VJJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemost 1995; 74: 1606-7.
• 36 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-80.
• 37 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
• 38 Koeleman BPC, Reitsma PH, Allaart RC, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
• 39 Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
• 40 Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M. Incidence of activated protein C resistance caused by the Arg 506 Gln mutation in factor V in 113 unrelated symptomatic protein C deficient patients. Blood 1995; 86: 219-24.
• 41 Zoller B, Svensson PJ, Dahlback B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood 1998; 91: 2210-1.